
|Articles|September 7, 2012
Safety Tolerability footer references
Advertisement
References 1. Data on File, 309560. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with
fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [published errata
appears in
J Clin Oncol.
2011;29(16):2293]
J Clin Oncol
. 2010;28(30):4594-4600. 3. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
2
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
3
What Does the Future Hold for Immune Effector Cell Therapies?
4
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
5





















































